Anxiolytic-like action of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region

European Journal of Pharmacology

Volumn 354, Issue 2-3, 1998, Pages 123-133

  Hasenöhrl, Rüdiger U ^a   Jentjens, Olaf ^a   De Souza Silva, M Angelica ^a   Tomaz, Carlos ^b   Huston, Joseph P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anxiogenic; Anxiolytic; Basal forebrain; Elevated plus maze; Neurokinin; Social interaction

Indexed keywords

SUBSTANCE P;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; NONHUMAN; OLIVARY NUCLEUS; PRIORITY JOURNAL; RAT; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; FEAR; MALE; MAZE LEARNING; RATS; RATS, WISTAR; SOCIAL BEHAVIOR; SUBSTANCE P; SUBSTANTIA INNOMINATA;

EID: 0344734161     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00441-5     Document Type: Article

References (54)

1. Aguiar, M.S., Brandao, M.L., 1996. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test. Physiol. Behav. 60, 1183-1186.
2. Almay, B.G.L., Johansson, F., Von Knorring, L., Le Greves, P., Terenius, L., 1988. Substance P in CSF of patients with chronic pain syndromes. Pain 33, 3-9.
3. Banks, W.A., Kastin, A.J., 1985. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res. Bull. 15, 287-292.
4. Bannon, M.J., Haverstick, D.M., Shibata, K., Poosch, M.S., 1991. Preprotachykinin gene expression in the forebrain: regulation by dopamine. Ann. N.Y. Acad. Sci. 632, 31-37.
5. Berntson, G.G., Hart, S., Sarter, M., 1997. The cardiovascular startle response: anxiety and the benzodiazepine receptor complex. Psychophysiology 34, 348-357.
6. Beuzen, A., Belzung, C., 1995. Link between emotional memory and anxiety states: a study by principal component analysis. Physiol. Behav. 58, 111-118.
7. Boix, F., Sandor, P., Nogueira, P.J.C., Huston, J.P., Schwarting, R.K.W., 1995. Relationship between dopamine release in nucleus accumbens and place preference induced by substance P injected into the nucleus basalis magnocellularis region. Neuroscience 64, 1045-1055.
8. Cruz, A.P.M., Frei, F., Graeff, F.G., 1994. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49, 171-176.
9. Dawson, G.R., Crawford, S.P., Collinson, N., Iversen, S.D., Tricklebank, M.D., 1995. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology 118, 316-323.
10. Decker, M.W., Brioni, J.D., Bannon, A.W., Arneric, S.P., 1995. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci. 56, 545-570.
11. De Lima, T.C.M., Baretta, I.P., Assreuy, J., 1997. Nitric oxide involvement in the anxiogenic effect of substance P in mice in the elevated plus-maze. Soc. Neurosci. Abstr. 23, 1859.
12. 3 antagonist (BRL 46470A) injected into basolateral amygdala, as opposed to diazepam. Behav. Brain Res. 59, 141-145.
13. De Souza Silva, M.A., Schwarting, R.K.W., Tomaz, C., Hasenöhrl, R.U., Huston, J.P., 1997. Basal forebrain injection of substance P increases extracellular acetylcholine in the frontal cortex. Soc. Neurosci. Abstr. 23, 1859.
14. File, S.E., 1986. Aversive and appetitive properties of anxiogenic and anxiolytic agents. Behav. Brain Res. 21, 189-194.
15. File, S.E., 1993. The social interaction test of anxiety. Neurosci. Protocols, 010-01-01-07.
16. 1 receptor antagonist in the social interaction test. Pharmacol. Biochem. Behav. 58, 747-752.
17. Gardner, C.R., Guy, A.P., 1984. A social interaction model of anxiety sensitive to acutely administered benzodiazepines. Drug Dev. Res. 4, 207-216.
18. Gerfen, C.R., 1991. Substance P (neurokinin-1) receptor mRNA is selectively expressed in cholinergic neurons in the striatum and basal forebrain. Brain Res. 556, 165-170.
19. Guard, S., Watson, S.P., 1991. Tachykinin receptor types: classification and membrane signaling mechanisms. Neurochem. Int. 18, 149-165.
20. Handley, S.L., McBlane, J.W., Critchley, M.A.E., Njung'e, K., 1993. Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav. Brain Res. 58, 203-210.
21. Hasenöhrl, R.U., Nichau, C., Frisch, C., De Souza Silva, M.A., Huston, J.P., Mattern, C.M., Häcker, R., 1996. Anxiolytic-like effect of combined extracts of zingiber officinale and ginkgo biloba in the elevated plus-maze. Pharmacol. Biochem. Behav. 53, 271-275.
22. Hernadi, I., Karadi, Z., Faludi, B., Lenard, L., 1997. Disturbances of neophobia and taste-aversion learning after bilateral kainate microlesions in the rat pallidum. Behav. Neurosci. 111, 137-146.
23. Huston, J.P., Hasenöhrl, R.U., 1995. The role of neuropeptides in learning: focus on the neurokinin substance P. Behav. Brain Res. 66, 117-127.
24. Huston, J.P., Hasenöhrl, R.U., Boix, F., Gerhardt, P., Schwarting, R.K.W., 1993. Sequence-specific effects of neurokinin substance P on memory, reinforcement, and brain dopamine activity. Psychopharmacology 112, 147-162.
25. Izquierdo, I., Cunha, C., Medina, J.H., 1990. Endogenous benzodiazepine modulation of memory processes. Neurosci. Biobehav. Rev. 14, 419-424.
26. Krappmann, P., Hasenöhrl, R.U., Frisch, C., Huston, J.P., 1994. Self-administration of neurokinin SP into the ventromedial caudate-putamen in rats. Neuroscience 62, 1093-1101.
27. Krauth, J., 1988. Distribution-free Statistics: An Application-oriented Approach. Elsevier, Amsterdam, pp. 34-38.
28. 2 receptor, substance P and enkephalin messenger RNAs in the neurons projecting from the nucleus accumbens. Neuroscience 82, 767-780.
29. Myers, R.D., 1966. Injection of solutions into cerebral tissue: relation between volume and diffusion. Physiol. Behav. 1, 171-174.
30. Napier, T.C., Mitrovic, I., Churchill, L., Klitenick, M.A., Lu, X.Y., Kalivas, P.W., 1995. Substance P in the ventral pallidum: projection from the ventral striatum, and electrophysiological and behavioral consequences of pallidal substance P. Neuroscience 69, 59-70.
31. Oehme, P., Krivoy, W.A., 1983. Substance P: a peptide with unusual features. Trends Pharmacol. Sci. 4, 521-523.
32. Otsuka, M., Yoshioka, K., 1993. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73, 229-308.
33. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, New York.
34. Pellow, S., Chopin, P., File, S.E., Briley, M., 1985. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14, 149-167.
35. Pernow, B., 1983. Substance P. Pharmacol. Rev. 35, 85-141.
36. Popovic, M., Jovanova-Nesic, K., Popovic, N., Bokonjic, D., Dobric, S., Rosic, N., Rakic, L., 1996. Behavioral and adaptive status in an experimental model of Alzheimer's disease in rats. Int. J. Neurosci. 86, 281-299.
37. Quirion, R., Dam, T.V., 1988. Multiple neurokinin receptors: recent developments. Regul. Pept. 22, 18-25.
38. Saria, A., Troger, J., Zernig, G., 1993. Different behavioral profiles of the non-peptide substance P (NK-1) antagonists CP-96,345 and RP 67580. Regul. Pept. 46, 346-348.
39. Sarter, M., Schneider, H.H., 1988. High density of benzodiazepine binding sites in the substantia innominata of the rat. Pharmacol. Biochem. Behav. 30, 679-682.
40. Shults, C.W., Quirion, R., Chronwall, B., Chase, T.N., O'Donohue, T.L., 1984. A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system. Peptides 5, 1097-1128.
41. Sprick, U., Hasenöhrl, R.U., Krauth, J., Klapdor, K., Huston, J.P., 1996. Effects of chronic substance P treatment and intracranial fetal grafts on learning after hippocampal kainic acid lesions. Peptides 17, 275-285.
42. Spyraki, C., Fibiger, H.C., 1988. A role for the mesolimbic dopamine system in the reinforcing properties of diazepam. Psychopharmacology 94, 133-137.
43. Starr, M.S., James, T.A., Gaytten, D., 1978. Behavioural depressant and antinociceptive properties of substance P in the mouse: possible implication of brain monoamines. Eur. J. Pharmacol. 48, 203-212.
44. Stoehr, J.D., Wenk, G.L., 1995. Effects of age and lesions of the nucleus basalis on contextual fear conditioning. Psychobiology 23, 173-177.
45. Teixeira, R.M., Santos, A.R.S., Ribeiro, S.J., Calixto, J.B., Rae, G.A., De Lima, T.C.M., 1996. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 311, 7-14.
46. Tomaz, C., Huston, J.P., 1986. Facilitation of conditioned inhibitory avoidance by post-trial peripheral injection of substance P. Pharmacol. Biochem. Behav. 25, 469-472.
47. Tomaz, C., Brandao, M.L., Garcia-Cairasco, N., 1992. Overlapping neural substrates underlying defense reactions, aversive memory, and convulsive behavior. In: Butcher, L.L., Decker, M., Lewin, E. (Eds.), Neurotransmitter Interactions and Cognitive Functions. Birkhäuser, Boston, MA, pp. 240-256.
48. Tomaz, C., Dickinson-Anson, H., McGaugh, J.L., De Souza-Silva, M.A., Viana, M.B., Graeff, F.G., 1993. Localization in the amygdala of the amnestic action of diazepam on emotional learning. Behav. Brain Res. 58, 99-105.
49. 2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology 121, 186-191.
50. Widgiz, S.L.M., Beck, C.H.M., 1990. Diazepam effects on the exploratory behaviour of rats in an elevated runway: evidence for biphasic effects of benzodiazepines. Behav. Brain Res. 40, 109-118.
51. Yamaguchi, K., Nakajima, Y., Nakajima, S., Stanfield, P.R., 1990. Modulation of inwardly rectifying channels by substance P in cholinergic neurons from rat brain in culture. J. Physiol. 426, 499-520.
52. 3H]2-oxo-quazepam (SCH 15-725) to localize BZ-1 receptors in the rat brain. Neurosci. Lett. 88, 86-92.
53. 1) receptor antagonist (±)-CP-96,345 causes sedation and motor impairment in Swiss albino mice in the black-and-white box behavioral paradigm. Neurosci. Lett. 143, 169-172.
54. 1) antagonist CP-96,345 and RP 67580 in Swiss albino mice in the black-and-white box. Neurosci. Lett. 151, 64-66.